anonymous
Guest
anonymous
Guest
God help you if you believe adult indication will help this drug. The response from my targets has been quite literally nonexistent. Supernus really just does not understand the pharmaceutical business and that should be evident to everyone at this point. It is Not going to turn around and be some blockbuster. Could it continue to grow at a very nominal pace for the next few years? Yes, but here’s the problem for you math geniuses. TXR and OXR were $900-1200 respectively in a lot of places so when you sold a few scripts Supernus could afford to pay you a decent bonus. Qelbree is $300 they are literally halving the profit with you most likely right now at the $75 per script mark. The bonus plan is very generous. The problem is............ there’s no prescriptions be written. I too have an interview this week and if you have half a brain you will get your affairs in order as well.